NeuroMab™ Anti-EGFR BBB Shuttle Antibody(NRZP-1022-ZP3845)

Figure 1 is a graph (FACS graph) showing the results of binding kinetics of P1X, P2X and P3X antibodies to EGFR on A431 cells measured by flow cytometry.

Figure 2 is a graph showing the results of a phospho-EGFR (pEGFR) ELISA showing that pEGFR is inhibited by a single antibody single agent treatment with P1X, P2X or P3X antibodies.

Figure 3 is a graph showing the results of a phospho-EGFR (pEGFR) ELISA (circles) and a phospho-ERK (pERK) ELISA (triangles), demonstrating inhibition by the 2:2:1 combination of P1X:P2X:P3X.

Figure 4 is a graph showing the results of a phospho-ERK (pERK) ELISA demonstrating the inhibitory effect of a 2:2:1 formulation of P1X:P2X:P3X (P1X+P2X+P3X) compared to P1X single antibody alone.

Figure 5 is a graph showing the results of a phospho-ERK (pERK) ELISA demonstrating the inhibitory effect of P1X+P2X+P3X on P2X monoantibody alone.

Figure 6 is a bar graph showing the results of Western blot analysis of total EGFR (tEGFR) internalization kinetics of H1975 cells pretreated with P1X+P2X+P3X antibodies for different periods of time prior to stimulation with EGF.

Figure 7 is a graph showing the results of a cell viability assay of HCC827 cells demonstrating the inhibition of tumor cell proliferation by treatment with P1X+P2X+P3X antibodies compared to cetuximab in the presence of EGF ligand.

Figure 8 is a graph showing the experimental results of DU145 tumor xenograft mouse model, showing that the tumor volume in mice treated with P1X+P2X+P3X antibodies was reduced compared with PBS and cetuximab controls.

Figure 9 is a graph showing the results of a ligand antagonism cell binding assay demonstrating the EGF ligand blocking ability of P1X, P2X or P3X alone at low doses.

Figure 10 is a graph showing the results of a ligand antagonism cell binding assay demonstrating the EGF ligand blocking ability of P1X, P2X or P3X alone or in triple combination at high doses.

Figure 11 is an immunoblot of an EGF receptor downregulation assay in cells pretreated with a triple combination of P1X+P2X+P3X or P1X Fab+P2X Fab+P3X Fab or with cetuximab. The housekeeping protein PCNA was used as a control.

Figure 12 is a graph showing the results of an experiment in a patient-derived colorectal cancer tumor xenograft mouse model, showing tumor volume in vivo in mice treated with ca+P2X+P3X antibodies and irinotecan alone and in combination, compared to PBS controls decrease.